Abstract
Background: The polycystic ovary syndrome (PCOS) is the commonest endocrine disorder in women of reproductive age and shows substantial phenotypic variability. According to the presence of the three diagnostic criteria of PCOS, i.e. oligo- and/or anovulation, hyperandrogenemia and/or clinical signs of high androgen levels, and polycystic ovaries, four different phenotypes of PCOS are identified. It appears that these phenotypes differ in the prevalence of several established and emerging cardiovascular risk factors. Methods: We searched the literature for studies that compared the cardiovascular risk profile of patients with the different phenotypes of PCOS. Results: Patients with both anovulation and hyperandrogenemia have more pronounced insulin resistance and higher levels of proinflammatory and prothrombotic mediators than patients with polycystic ovaries and either anovulation or hyperandrogenemia. Conclusion: Given that these differences appear to be mainly driven by the more pronounced obesity of the former patients, diet and exercise aiming at weight loss should constitute the cornerstone of management of PCOS and should be particularly emphasized in patients with the higher risk phenotypes of the syndrome.
Keywords: Polycystic ovary syndrome, phenotypes, diagnostic criteria, anovulation, hyperandrogenemia, polycystic ovaries, cardiovascular risk.
Call for Papers in Thematic Issues
Accelerating Cancer Drug Discovery Using Artificial Intelligence and In Silico Methods
Artificial intelligence and in silico methods speed up cancer drug discovery, transforming how new treatments are developed. Artificial intelligence, along with in silico methods, allows for quick investigation of large biological datasets, helping identify potential drug targets with remarkable speed and accuracy. Machine learning models help us understand how molecules ...read more
Artificial Intelligence and Computational Approaches in Drug Discovery
Computer-aided drug design (CADD) and artificial intelligence (AI) are fundamentally reshaping drug discovery pipelines by significantly enhancing efficiency in molecular screening, rational drug design, and natural product development. In the field of molecular screening, the integration of virtual high-throughput screening with advanced AI models enables rapid analysis of million-compound libraries, ...read more
Artificial Intelligence for Transformative Healthcare: From Prediction to Prevention
Machine learning and deep learning are transforming biomedical diagnosis by allowing for quicker and more accurate disease detection, ultimately enhancing patient care. Using advanced algorithms and extensive medical data, these approaches uncover patterns that may not be visible to humans, resulting in better detection of conditions such as cancer and ...read more
Management Of Primary And Metastatic Hepatic And Biliary Cancer
Cancer of the liver (primary and metastatic) and of the biliary tract is common wordwide. The pathophysiology is diverse. The therapeutic measures for the cancer of the liver and biliary tract include chemotherapy, surgery, transplantation, radiotherapy, immunotherapy and others. The aim of this thematic issue is to summarize the state-of-the-art ...read more
Related Journals
Anti-Cancer Agents in Medicinal Chemistry
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Current Bioactive Compounds
Current Cancer Drug Targets
Combinatorial Chemistry & High Throughput Screening
Current Cancer Therapy Reviews
Current Diabetes Reviews
Current Drug Safety
Current Drug Targets
Current Drug Therapy
Related Books
The Role of Nutraceuticals in Degenerative Diseases (Part 2)
Herb-Drug Interactions: A Medicinal Approach
The Role of Nutraceuticals in Degenerative Diseases (Part 1)
Autoimmune Disorders and Secondary Plant Metabolites (Part 2)
Autoimmune Disorders and Secondary Plant Metabolites (Part 1)
Brain Tumor Drug Development: Current Advances and Strategies (Part 2)
The Role of Asymmetric Synthesis in Drug Discovery
Brain Tumor Drug Development: Current Advances and Strategies (Part 1)
Handbook of Practical Pharmacology - I
Drug Repurposing for Antivirals
46
4
1
1